BTIG Research Raises Humacyte (NASDAQ:HUMA) Price Target to $11.00

Humacyte (NASDAQ:HUMA – Free Report) had its price objective upped by BTIG Research from $8.00 to $11.00 in a research note published on Monday morning, Benzinga reports. BTIG Research currently has a buy rating on the stock. A number of other research firms also recently issued reports on HUMA. Piper Sandler reiterated a neutral rating […]

Leave a Reply

Your email address will not be published.

Previous post Shore Capital Reaffirms Hold Rating for Spectris (LON:SXS)
Next post The health problems that can afflict high level business leaders and how these can be prevented